Biovitrum AB and Swedish Orphan AB combine to form Swedish Orphan Biovitrum.

Biovitrum and Swedish Orphan will be combined forming Swedish Orphan International AB (Swedish Orphan) Biovitrum with pro forma revenues 2009 of approximately SKR 2 bn and an EBITDA margin of 15%. Biovitrum will pay an upfront consideration of SKR 3.5 bn (on a cash and debt free basis), to be financed by a fully guaranteed rights issue, an issue in kind and bank financing. The Transaction will be instantly accretive to earnings/share for Biovitrum's shareholders. Biovitrum AB (publ) and Swedish Orphan International AB will be combined forming Swedish Orphan Biovitrum. Biovitrum and Swedish Orphan share the same mission and business philosophy of developing and making available orphan …